Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 2, 2004, Pages 164-170

  Brizzi, Patrizia ^a   Tonolo, Giancarlo ^a   Bertrand, Graziano ^b   Carusillo, Francesca ^a   Severino, Cristiana ^a   Maioli, Mario ^a   Malaguarnera, Lucia ^c   Musumeci, Salvatore ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b General Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antioxidized low density lipoprotein (LDL) antibody; Atherosclerosis; Conjugated diene; Oxidized LDL (ox LDL)

Indexed keywords

ALKADIENE; ATORVASTATIN; AUTOANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET RESTRICTION; DOSE RESPONSE; ENZYME IMMUNOASSAY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BETA-THALASSEMIA; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MIDDLE AGED; OXIDATION-REDUCTION;

ANIMALIA;

EID: 1642443936     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.030     Document Type: Article

References (30)

1. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisemberg S. Plasma triglycerides determines structure-composition in low and high density lipoprotein. Arteriosclerosis 1984;4:225-31.
2. Ahotupa M, Ruutu M, Mantila E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem 1996;29:139-44.
3. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains α-helical and collagen like coiled coils. Nature 1990;343:531-5.
4. Negre-Salvayre A, Fitoussi G, Reaud V, Pieraggi MT, Thiers JC, Salvare R. Oxidized LDL in cultured bovine aortic endothelial cells elicits a delayed and sustained rise of cytosolic calcium. FEBS Lett 1992;299:60-5.
5. Lehr H, Hubner C, Nolte D, Finckh B, Beisiegel U, Kohlschutter A, et al. Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med 1991;191:85-90.
6. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, et al. Lysophosphatidlylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994;269:31430-5.
7. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996;16:1074-9.
8. Shoji T, Nishizava Y, Fukumoto M, Shimamura K, Rimura J, Kanda H, et al. Inverse relationship between circulating oxidized low-density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000;148:171-7.
9. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund O. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18: 1203-11.
10. Lehtimaki T, Lehtinen S, Nikkila M, Jaakkola O, Jokela H, Yla-Herttuala S, et al. Autoantibodies against oxidized low-density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-8.
11. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000;20:703-7.
12. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992;13:341-90.
13. Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, et al. Oxidative stress and antioxidant status in β-thalassemia major: Iron overload and depletion of lipid soluble antioxidants. Blood 1996;88:3608-14.
14. Tesoriere L, D'Arpa D, Maggio A, Giaccone V, Pedone E. Oxidation resistance of LDL is correlated with vitamin E status in β-thalassemia intermedia. Atherosclerosis 1998;137:429-35.
15. Livrea MA, Tesoriere L, Maggio D, D'Arpa D, Pintaudi AM, Pedone E. Oxidative modification of low density lipoprotein and atherogenetic risk in β-thalassemia. Blood 1998;92:3936-42.
16. Brizzi P, Isaja T, D'Agata A, Malaguarnera L, Malaguarnera M, Musumeci S. Oxidized LDL antibodies (OLAB) in patients with β-thalassemia major. J Atheroscl Thromb 2002;9:139-44.
17. Zurlo MG, De Stefano P, Borgna Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and cause of death in thalassemia major. Lancet 1989;1:27-30.
18. Borgna Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, et al. Thromboembolic events in beta-thalassemia major: An Italian Multicenter Study. Acta Haematol 1998;99:76-9.
19. Brizzi P, Tonolo G, Carusillo F, Malaguarnera M, Maiolo M, Musumeci S. Plasma lipid composition and LDL oxidation. Clin Chem Lab Med 2003;41:56-60.
20. Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol 1986;155-68.
21. Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD. Diabetic nephropathy in hypertransfused patients with β-thalassemia. The role of oxidative stress. Diabetes Care 1998;21:1306-9.
22. Raal FJ, Areias AJ, Waisberg R, von Arb M. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolemia. Atherosclerosis 1995;115:9-15.
23. Hansson G, Holm J, Holm S, Fovet Z, Hedric HJ, Fingerle J. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA 1991;88:10530-4.
24. Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995;96:1389-94.
25. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients coronary heart disease: The Scandinavian Survival study (4S). Lancet 1994;344:1383-9.
26. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, et al. Additive effects of simvastatin beyond its effects on LDL-cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Inv 2000;30:980-7.
27. Rajavashisth TB, Andlalibi A, Turrito MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factor by modified low density lipoprotein. Nature 1990;344:254-7.
28. Brown MS, Goldstein A. Scavenging for receptor. Nature 1990;343:508-9.
29. Yla-Herttuala S, Palinski W, Butler S, Picard S, Steimberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized low density lipoprotein. Arterioscler Thromb 1994;14:32-40.
30. Khoo JC, Miller E, Pio F, Steimberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992;12:1258-66.